Background: To explore the current landscape of seasonal influenza vaccination across China, and estimate the budget of implementing a national ''free-at-the-point-of-care" vaccination program for priority populations recommended by the World Health Organization. Methods: In 2014 and 2016, we conducted a survey across provincial Centers for Disease Control and Prevention to collect information on regional reimbursement policies for influenza vaccination, estimated the national uptake using distributed doses of influenza vaccines, and evaluated the budget using population size and vaccine cost obtained from official websites and literatures. Results: Regular reimbursement policies for influenza vaccination are available in 61 mutually exclusive regions, comprising 8 provinces, 45 prefectures, and 8 counties, which were reimbursed by the local Government Financial Department or Basic Social Medical Insurance (BSMI). Finance-reimbursed vaccination was offered mainly for the elderly, and school children for free in Beijing, Dongli district in Tianjin, Karamay, Shenzhen and Xinxiang cities. BSMI-reimbursement policies were limited to specific medical insurance beneficiaries with distinct differences in the reimbursement fractions. The average national vaccination coverage was just 1.5-2.2% between 2004 and 2014. A free national vaccination program for priority populations (n = 416 million), would cost government US$ 757 million (95% CI 726-789) annually (uptake rate = 20%). Conclusions: An increasing number of regional governments have begun to pay, partially or fully, for influenza vaccination for selected groups. However, this small-scale policy approach has failed to increase national uptake. A free, nationwide vaccination program would require a substantial annual investment. A cost-effectiveness analysis is needed to identify the most efficient methods to improve coverage.
Introduction
Annual seasonal influenza epidemics represent a major disease burden globally, with 3-5 million cases of severe illness that result in over a quarter of a million deaths every year [1] . Influenza vaccination is the most effective way to prevent disease, and the World Health Organization (WHO) recommends annual seasonal influenza vaccination for pregnant women, children aged six to 59 months, the elderly, persons with specific chronic medical conditions, and health-care workers (hereafter called the ''priority populations") [2] . As of 2014, over 100 countries worldwide already have seasonal influenza vaccination policies that recommend vaccination of at least one of the risk groups [3] . Over 40% of countries list seasonal influenza vaccination on their National Immunization Schedule, including most countries across and South America, Europe, and some countries in African, SouthEast Asia, and the West Pacific Region [4] [5] [6] [7] [8] .
Despite seasonal influenza being associated with between 67,000 and 430,000 annual excess respiratory and circulatory deaths on average for five pre-pandemic influenza seasons 2004-2005 through 2008-2009 [9] , influenza vaccination is not included on the National Immunization Program (NIP) in China. Therefore, there are no national guidelines for alleviating the cost burden on individuals who wish to receive the vaccine, which may contribute to low vaccine uptake of 1Á9% for the entire population in China and 4.3% for the urban residents aged above 60 years old in 9 cities, recorded during the 2008-2009 and 2011-2012 influenza season, respectively [10, 11] . Thus, vaccine uptake in China falls substantially below the World Health Assembly (WHA) target of 75% in the elderly by 2010 [12] , and also below that of other upper-middle income countries such as Brazil where coverage is over 70% in the elderly [6] .
In countries where vaccination costs are subsidized by the respective governments, there is higher national vaccine uptake [13, 14] . To our knowledge, only a handful of large cities in China currently provide reimbursement for influenza vaccination. For example, since 2007, Beijing has provided free seasonal influenza vaccination to the elderly and school children, and since 2004, Xi'an city in Shaanxi province has provided free vaccination to those covered by Medicare insurance [10] . Unlike NIP vaccines funded by the central government, there is a diverse patchwork of reimbursement policies that exist at the provincial, prefecture and county levels for influenza vaccination.
WHO has called upon China to include more vaccines in NIP, following a recent vaccine scandal with improperly refrigerated of transported vaccines sold nationwide [15] . To inform a future national government-funded free seasonal influenza vaccination program for China that harnesses the advantages of regionally administrated schemes and provides a sustainable public health strategy, we conducted a survey to explore the current landscape of influenza vaccination, including reimbursement policies, eligible subgroup sizes, and influenza vaccine uptake across China. We then estimate the budget needed to implement a nationwide ''free-at-the-point-of-care" vaccination program by conducting a budget impact analysis parameterized with province-level data for the size of the subgroups-delineated by age and risk group-eligible to receive an influenza vaccine.
Methods

Landscape of influenza vaccination across China
Regional reimbursement policies for influenza vaccination
Between August and November, 2014, we conducted a survey across all 31 provincial Centers for Disease Control and Prevention (CDCs) to collect information on provincial-level reimbursement policies for influenza vaccination (and at the prefecture-and county-level if applicable), and performed a web search of below official websites to validate the responses: (1) all 31 provinciallevel and 333 prefecture-level governments, (2) the Bureau of Human Resources and Social Security, (3) the Commission of Health and Family Planning, and (4) the provincial CDCs (see questionnaire in supplementary 1). Nearly two years have passed since our initial survey mentioned above. To check whether there were major new vaccination policies implemented across China between December 2014 and September 2016, we re-searched all the aforementioned official websites.
Eligible subgroup size of regional reimbursement policies
For the regions where reimbursement policies are available for influenza vaccination, the eligible population mainly include subgroups at a certain age, school children, health-care workers, and/or insured persons of Basic Social Medical Insurance (BSMI) (including New Rural Cooperative Medical Insurance for Rural Residents (NRCMI), Basic Social Medical Insurance for Urban Employees (BSMIUE), and Basic Social Medical Insurance for Urban Residents (BSMIUR)) (see details for the introduction to BSMI in supplementary 2). To estimate the size of subgroups eligible for reimbursement, local age-specific population data and the number of school children were obtained from National Bureau of Statistics [16] , the number of health-care workers was gained from local Health Statistics Yearbook, and the number of insured persons was collected from the four official websites described above.
Influenza vaccine coverage
We estimated the national yearly influenza vaccine uptake rate in China using the annual number of doses of seasonal influenza vaccine released between 2004 and 2014 from the website of the National Institutes for Food and Drug Control. In China, all unsold influenza vaccines are returned to the manufacturers at the end of each season for disposal. We used a 14-31% return rate [10] , and 1-10% vaccine wastage rate, resulting from physical damage, expiration, losses in transit, consistent with the wastage of single dose vaccines in 7 GAVI-eligible countries [17] [18] [19] .
Budget impact analysis under a free national vaccination program for priority populations
The size of priority populations
We used 2013 National Bureau of Statistics age-specific population data to estimate the size of priority populations stratified by provinces [16] . According to the latest guidelines of influenza vaccination issued by China CDC [20] , the priority populations for influenza vaccination in China includes those recommended by WHO [2] , and family members and caregivers of infants younger than 6 months. For global comparisons, we used the WHO definition of priority populations. The detailed calculation of priority populations size was provided below.
We estimated the number of pregnant women as the sum of number of live births, still births, fetus deaths and abortions. The number of live births was obtained from China Health Statistical Yearbook (CHSY) in 2013 [21] . The number of still birth and fetus deaths were estimated as the product of the number of perinatal deaths [21] and the fraction of those deaths which are still births and fetus deaths (68.59%) [22] . We estimated the number of abortions by dividing the number of induced abortions [21] by the proportion of induced abortions (88.54%) [23] . The number of health-care workers was obtained from the CHSY in 2013 [21] . To minimize the overlap among persons with specific chronic medical conditions, children aged six to 59 months and the elderly, we estimated the number of persons with chronic illness only in those aged 5-59 years, multiplying the age-specific population size by the age-specific prevalence of chronic conditions.
We performed a literature review to obtain the prevalence of underlying medical conditions in China which are related to increased risk of hospitalization and mortality if infected with influenza. We searched articles published in PubMed, Wanfang and CNKI during 2000-2014, with terms including above specific disease as ''asthma" and ''China", and ''prevalence"/''disease bu rden"/''epidemic"/''epidemiological"/''epidemiology". All identified papers were reviewed, and the most recent national representative studies were included [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . We summed the prevalence of each chronic disease to get the prevalence by diseases (e.g., a person with three chronic diseases was counted three times) ( Table 1) . To get the prevalence by cases (e.g., a person with more than one chronic diseases was counted only one time), we multiplied prevalence by diseases with a ratio of prevalence by cases to prevalence by diseases, which was obtained from the 4th National Health Service Survey of China in 2008 [35] (Table 1) . We specifically estimated the size of priority populations in regions with reimbursement policies as well, using the same methods for estimating that stratified by provinces described above.
Budget impact analysis
We evaluated the budget necessary for a free-at-the-point-ofcare trivalent inactivated influenza vaccine (TIV) program for priority populations. TIV is administered in doses of 0Á25 ml for infants 6-35 months, and 0Á50 ml for the rest of the population [20] . Considering the very low uptake rate [10] of influenza vaccines in China, we assumed conservatively that children aged 6 months to 8 years will have never received an influenza vaccine and therefore would require two doses in the first year of the program. There is significant uncertainty in the coverage that may be achieved in a potential national free vaccination program. The experience of Beijing showed that the uptake in the elderly increased substantially (1.69% in 1999 vs. 43% in 2010) [40, 41] after free influenza vaccination was offered in 2007. It is likely that the uptake in other less dense and development provinces would not increase as quickly as Beijing, the capital of China where residents likely have greater access to health care facilities and there are likely disproportionately more educated persons. We estimated the budget with a conservative base-case uptake rate of 20% [42] and a conservative vaccine wastage rate of 10% [17] . We also conducted a sensitivity analysis to estimate the impact of uncertainty of uptake rate (10%, 40% and 75%), and wastage rate (lower limit = 1%) [17] on the total budget. Moreover, we used agespecific vaccine uptake as well as risk-group-specific vaccine uptake (40% for children aged 6-59 months, 20% for the elderly, persons aged 5-59 years with underlying chronic illness and health-care workers, and 10% for pregnant women, according to the difference in uptake rates which was observed in nine cities in China [11] ) to estimate the national budget.
Influenza vaccine types that are used in specific regions are determined and centralized purchased by local provincial, prefecture or even district level CDCs, and then distributed to lower level CDCs and/or Points of Vaccination [43] . Procurement of influenza vaccine is conducted by negotiated between government and manufactures. To obtain the influenza vaccine cost in China, we searched the official websites of provincial and prefecture-level authorities, which included the Price Bureau, Development and Reform Commission, Health Bureau, CDCs and government portal website. When considering the overall vaccination program costs (including training, advocacy, etc.) (US$1.27 per dose for the provincial Expanded Program on Immunization in Guizhou province) [44] , and assuming the existing cold-chain infrastructure could be used for a national seasonal influenza vaccination program, the influenza vaccination cost per capita during 2011-2013 was separately US$4.87 per dose (95%CI 4.62-5.11) for 0.25 ml formulation and US$7.17 per dose (95%CI 6.89-7.46) for 0.50 ml formulation. All costs were updated to 2015 CNY using the consumer price index [45] and expressed in US dollars using the median 2015 exchange rate of 1 US$ = 6Á2 CNY [46] .
Results
Landscape of influenza vaccination across China
Regional reimbursement policies for influenza vaccination
Regular reimbursement policies for influenza vaccination are available in 61 mutually exclusive regions across China, comprising 8 out of 31 provinces, 45 out of other 253 prefectures and 8 out of remaining 1782 counties. Influenza vaccination in these regions was reimbursed fully or partially by the local Government Financial Department (hereafter called Finance-reimbursed vaccination), or BSMI. According to the BSMI types and reimbursement modes, the BSMI-reimbursed policy was further broken down into 3 subgroups: (1) NRCMI-reimbursed vaccination; (2) BSMIproportional-reimbursed vaccination, which was proportionally reimbursed by BSMIUE and/or BSMIUR; (3) BSMIUE-MSAreimbursed vaccination which was reimbursed using an individual card of Medical Savings Account (MSA) of BSMIUE.
Annual Finance-reimbursed vaccination is offered free of charge in Beijing, Dongli district in Tianjin, Karamay in Xinjiang province, Shenzhen in Guangdong province and Xinxiang in Henan province. NRCMI-reimbursed vaccination is available in seven counties and one prefecture, BSMI-proportional-reimbursed vaccination available in five prefectures, and BSMIUE-MSA-reimbursed vaccination available in seven provinces and 38 prefectures (there are two types of policies available in Xinxiang and Shenzhen, respectively). There were also several one-off large-scale free influenza vaccination programs in a few cities (e.g., Chengdu of Sichuan province, and Jinzhou of Liaoning province), mainly as a result of natural disasters (e.g., 2008 earthquake in Sichuan province, and 2013 flood in Liaoning province). (Fig. 1 and Table 2 , and more details shown in supplementary Table 1s .) It's noted that BSMI-proportionalreimbursed vaccination for insured persons in Xi'an of Shaanxi province was only implemented between 2004 and 2006; in 2015, BSMI resumed reimbursement for influenza vaccination, i.e., urban employees can use the surplus fund of individual BSMIUE MSA card to pay for influenza vaccination for their own and their families.
Significant differences were also observed for the reimbursement fractions among these four reimbursement policies. For example, in BSMI-proportional-reimbursed vaccination regions, the reimbursement fraction ranged from 30% (Zhaoqing in Guangdong province) to 100% (e.g., Kaifeng in Henan province). Importantly, the reimbursement fraction of BSMIUE-MSA-paid vaccination relies on the availability of surplus funds in the individual BSMIUE-MSA accounts (Table 2) .
Eligible subgroup size of regional reimbursement policies
The eligibility criteria for reimbursement varied significantly. Annual Finance-reimbursed vaccination was mainly offered for the elderly, school children and health-care workers. BSMIreimbursement policies were limited to specific medical insurance beneficiaries. Considerable differences were observed for the number of eligible subgroups: Finance-reimbursed vaccination covered 5Á7 million persons, NRCMI-reimbursed vaccination covered 7Á2 million, BSMI-proportional-reimbursed vaccination covered 5Á8 million, and BSMIUE-MSA-reimbursed vaccination covered 102.8 million. The NRCMI-reimbursed vaccination covered over 70% of local population aged 6 months and over. The coverage of most of other reimbursed vaccination was less than 30% (Fig. 2) .
In regions with regular reimbursement policies, priority populations represented an average of 31% of the local population aged 6 months and above. In 59% (36/61, excluding Kaifeng and Inner Mongolia where the size of the eligible population was unavailable) of regions, the size of the eligible population was less than that of priority populations (Fig. 2) . In 86% (n = 50) of the 58 regions where influenza vaccination was reimbursed by BSMI, the policy focused on the insured persons irrespective of membership in a priority risk group (Table 2) . For example, there were 463,000 people in the priority populations in Changji of Xinjiang province, while only 238,300 urban employees registered in BSI-MUE were covered by BSMIUE-MSA-reimbursed vaccination.
Influenza vaccine coverage
Between 2004 and 2010, influenza vaccine supply increased by 235% from 17Á5 to 58Á8 million doses. This translates to a rise from 13Á6 to 44Á1 doses/1000 people, and on average 72Á2% of doses were manufactured in China. The sharp increases in dose distribution in the 2010-2011 influenza season were likely because of the greater social attention and public awareness surrounding the 2009 H1N1 pandemic. However, the influence of the pandemic on increased distribution did not last long. After 2010 the number of doses distributed nationally decreased by 35%, to near 2008 levels, with 28Á2 doses/1000 people in 2013. This drop was despite 45 of 61 regions beginning reimbursement policies in 2010 or later (Fig. 3) . Distributed influenza vaccines were only sufficient for 1Á3-3Á6% of the total population aged 6 months and over, and for between 4Á5 and 11Á5% of the priority populations in China throughout the period. Assuming a manufacture return rate of 31% [10] and a wastage rate of 10% [17] , the distributed influenza vaccines was on average sufficient to cover just 1Á5% of the total population between 2004 and 2014 (range: 0Á8% in 2004 to 2Á2% in 2010). Using a manufacture return rate of 14% [10] and a wastage rate of 1% [17] , the average uptake rate would be 2Á0% (range: 1Á1% in 2004 to 3Á1% in 2010).
3.2.
Budget impact analysis under a free national vaccination program for priority populations 3.2.1. The size of priority population The population aged six months and over was 1Á35 billion in 2013, of which 31.6% (426 million) would be included in the priority populations for influenza vaccination. Of these, 45% (193 million) were the elderly aged 60 years and above, 30% (129 million) were persons aged 5-59 years with underlying chronic illness, 17% (72 million) were children aged 6-59 months, the remaining 8% included pregnant women (22 million), and health-care workers (10 million). The size of the priority populations varied across provinces, ranging from 0Á8 million in Tibet province to 32Á1 million in Shandong province (Fig. 4A ).
Budget impact analysis
Assuming an uptake rate of 20% [42] and a vaccine wastage rate of 10% [17] , a free, government-funded national vaccination program for priority populations, would cost the Chinese government US$ 757 (95% CI 726-789) million annually for vaccine purchase and vaccination program operations. Included in this figure is US $ 309 (297-322) million for the elderly, US$ 210 (202-218) million for persons aged 5-59 years with underlying chronic illness, US$ 187 (178-195) million for children aged 6-59 months, US$ 36 (34-37) million for pregnant, and US$ 16 (14-16) million for health-care workers ( Table 3 ). The budget ranged from US$ 1.56 (1.50-1.63) million in Tibet province to US$ 56.73 (54.38-59.08) million in Shandong province (Fig. 4B ) (see province details in Table 3 ). The budget scales proportionally to the vaccine uptake rate. The national budget would be US$ 379 (363-394) million, US$ 1.514 (1.452-1.577) billion and US$ 2Á840 (2Á722-2Á957) billion at an uptake rate of 10%, 40% and 75%, respectively. When the wastage rate decreased to 1%, the national budget would be US $ 344 (330-358) million, US$ 688 (660-717) million, US$ 1.377 (1.320-1.434) billion and US$ 2.582 (2.474-2.688) billion at an uptake rate of 10%, 20%, 40% and 75%, separately. When agespecific and risk-group-specific uptake rates were used, the national budget would be US$ 926 (887-965) million and US$ 842 (806-878) billion at a wastage rate of 10% and 1%, respectively.
Discussion
The recent vaccine scandal, with massive improperly stored and distributed category 2 vaccines (refers to those used in private sector and paid out of pocket) sold in 24 provinces in China [47] , triggered heated debates over the regulation and management of category 2 vaccines. WHO recommends expanding China's category 1 vaccines (refers to those listed in NIP, which are procured and distributed under official arrangement, and provided free of charge) list [15] . The State Council of China released an amended regulation of circulation and management of vaccines. It requires category 2 vaccines to be distributed in the same way as category 1 vaccines [48] . All these may speed up including more category 2 vaccines in NIP.
The seasonal influenza vaccine is one kind of category 2 vaccines, with coverage far below the 2003 WHA targets of at least 75% of the elderly by 2010 [12] . Eliminating or reducing out-ofpocket expenses for vaccination is an important enabling factor for influenza vaccine uptake [13, 14, [49] [50] [51] [52] . To support Chinese government decision makers considering sustainable implementation of a national free influenza vaccination program, we evaluated the current landscape of influenza vaccination across China, and estimated the budget needed for such a program. We found that there was wide variation in seasonal influenza vaccination across provincial-, prefecture-and county-level governments with regards to funding, eligible populations, and reimbursement fractions across these regions.
Existing reimbursement policies were mainly confined to developed regions such as Beijing and Karamay, but were also present in a few less-developed, rural regions. In 86% of regions where influenza vaccination was partly or fully paid by BSMI, the policy focused on the insured persons irrespective of medical high-risk status. This mismatch between priority populations and populations eligible for reimbursement creates gaps in coverage and unequal access to vaccination for high risk groups. A national vaccine program ensuring that Immunization of the priority populations would have the largest public health benefit.
Our results suggest that the current reimbursement framework has failed to stimulate demand for influenza vaccination. Two possible reasons may account for this: First, the population eligible for reimbursement (n = 121.5 million) only accounts for about 9% of the national population. Thus, even substantial increases in uptake among groups eligible for reimbursement will have a very small impact on overall national uptake rates. Second, the specific reimbursement policies fail to motivate or incentivize vaccineseeking behavior. For example, in BSMIUE-MSA-reimbursed vaccination, the individual MSA is an exclusive account only used by the insured persons and sometimes their family members. MSA funds can be used to pay for outpatient and emergency services, as well as some other category 2 vaccines (e.g., Haemophilus Influenza B vaccine) [54] . Hence, the insured individuals typically are less willing to pay for influenza vaccination if they have higher demand for other outpatient medical services and limited funds in their MSA. The precise impact of different payment systems on the uptake of influenza vaccination is important and merits further investigations.
The 2011 dose distribution per 1000 population in China was lower than 88 other countries/regions [55] . Despite a general trend towards increased vaccine supply, the estimated uptake rate has remained low, on average 1Á5-2Á0% between 2004 and 2014. It was not possible to estimate the age-specific coverage rate in China using lot release data. However, even in Beijing, where free influenza vaccination has been provided to the residents aged 60 years and over since 2007, the coverage rate in the elderly in 2010 was 43Á1% [41] , which was far below the WHA target, and that in the US (66Á7% during the 2014-2015 influenza season) [56] , and Brazil (over 70% since 2001) [6] . WHA stated that better use of vaccines for seasonal epidemics will help to ensure that manufacturing capacity meets demand in a future pandemic [12] . This low coverage precluded any meaningful control of seasonal disease burden and negatively impacted China's preparedness for an influenza pandemic. To improve seasonal influenza vaccine coverage, reduce the disease burden and prepare for the next pandemic in China, will require political commitment and sustained public health investment. We evaluated the budget needed to fund a potential national program on influenza vaccination. This money (US$ 757 million, 95%CI 726-789) is 4.777‰ (4.579-4.975) of total government health expenditures and 0Á080‰ (0.077-0.083) of GDP in 2015. To quantify and compare such a program with other health-care decisions, it would be helpful to implement a cost-effectiveness analysis that incorporates the annual outlay due to vaccine costs (calculated in this study) as well as (1) the downstream cost savings through averted medical visits and deaths, and (2) the quality of life gained through decreased influenza-associated morbidity and mortality.
This was the first study to comprehensively collect influenza vaccine reimbursement information across China. Our online survey was conducted at the provincial-level CDCs because of the difficulty of contacting all district-level CDCs, a few of whom could not provide complete information for their entire province. Although we supplemented the survey data with information obtained from official websites, there was some missing information. In spite of this limitation, we believe this study provides a detailed picture of the current reimbursement policy landscape. Our budget analysis may underestimate total costs as we did not assess the need for additional investments in the vaccine cold chain that could be required to support a national influenza vaccination program.
Conclusions
This was the first detailed analysis of the landscape of influenza vaccine reimbursement policies across China. Although an increasing number of regional governments have begun to pay, partially or fully, for influenza vaccination for selected groups, this patchwork of small-scale sub-national policies have failed to increase national uptake of the vaccine, which remains low. A national, free seasonal influenza vaccination program for priority populations would be costly; a cost-effectiveness analysis is needed to identify the most efficient way to improve vaccination coverage rates and better control influenza disease burden in China.
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